President Trump told reporters that tariffs on pharmaceuticals would start at "25% or higher," but did not say when they ...

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2025 Fortune Media IP Limited ...

Merck MRK decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its investigational cancer drugs vibostolimab and favezelimab, respectively.

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Merck & Co has followed the lead of other big pharma groups like Pfizer and GlaxoSmithKline by hiving off its mature and off-patent drugs into a new company. The decision will take some 90 ...

Merck & Co has axed two hepatitis drugs in its pipeline, a further indication that competitors think the market has peaked. The company already markets Zepatier (elbasvir+grazoprevir), which got ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...

indicates confidence in the drug’s efficacy but still requires further data presentation for comprehensive evaluation. While the trial’s early success and Merck’s increased sales guidance ...